Redhill Biopharma Stock In The News
| RDHL Stock | USD 2.56 0.04 1.54% |
Our overall analysis of Redhill Biopharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Redhill Biopharma. The specific impact of Redhill Biopharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Redhill Biopharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Redhill Biopharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Redhill Biopharma Backtesting and Redhill Biopharma Hype Analysis. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Redhill |
Redhill Biopharma Today Top News and Investor Outlook
Redhill Biopharma Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Redhill and other traded companies coverage with news coverage. We help investors stay connected with Redhill headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Redhill Stock performance. Please note that trading solely based on the Redhill Biopharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Redhill Biopharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Redhill earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Redhill Biopharma that are available to investors today. That information is available publicly through Redhill media outlets and privately through word of mouth or via Redhill internal channels. However, regardless of the origin, that massive amount of Redhill data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Redhill Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Redhill Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Redhill Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Redhill Biopharma alpha.
Redhill Largest EPS Surprises
Earnings surprises can significantly impact Redhill Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-11-19 | 2019-09-30 | -0.4 | -0.35 | 0.05 | 12 | ||
2018-08-30 | 2018-06-30 | -0.44 | -0.5 | -0.06 | 13 | ||
2022-06-23 | 2022-03-31 | -0.23 | -0.3 | -0.07 | 30 | ||
2017-05-03 | 2017-03-31 | -0.57 | -0.5 | 0.07 | 12 | ||
2017-02-24 | 2016-12-31 | -0.67 | -0.6 | 0.07 | 10 | ||
2016-07-27 | 2016-06-30 | -0.58 | -0.51 | 0.07 | 12 |
Redhill Biopharma Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Redhill Biopharma Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of March 2025
Is GC Biopharma Corp. Trading At A percent Discount at simplywall.st
12th of March 2025
Short Interest in RedHill Biopharma Ltd. Rises By 486.2 at thelincolnianonline.com
11th of March 2025
Xeris Biopharma - Possibly The Best Pharma Stock at talkmarkets.com
10th of March 2025
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian 20... at gurufocus.com
7th of March 2025
BIO-Europe Spring 2025 Partnering is Surging - All Roads Lead to Milan for Biopharmas Prem... at finance.yahoo.com
6th of March 2025
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results and Announces 20... at businesswire.com
5th of March 2025
EyePoint Pharmaceuticals Reports Q4 Loss, Lags Revenue Estimates at finance.yahoo.com
4th of March 2025
Guillain-Barr Syndrome Drug Development Pipeline Research Report 2025 Featuring Annexon an... at finance.yahoo.com
3rd of March 2025
Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer at finance.yahoo.com
27th of February 2025
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, ... at gurufocus.com
20th of February 2025
Wall Street Analysts Predict a 127.26 percent Upside in Benitec Biopharma Heres What You S... at zacks.com
11th of February 2025
Stocks To Watch Quantum Biopharma Sees Relative Strength Rating Jump To 91 at investors.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Redhill Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Redhill Biopharma's short interest history, or implied volatility extrapolated from Redhill Biopharma options trading.
Check out Redhill Biopharma Backtesting and Redhill Biopharma Hype Analysis. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share | Quarterly Revenue Growth (0.28) | Return On Assets | Return On Equity |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.